Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer.

被引：0
|
作者：
Costa, David T. [1 ]
Grier, Shaylyn [1 ]
Perez, Melanie [1 ]
Gao, Li [1 ]
Villalona-Calero, Miguel A. [2 ]
Duan, Wenrui [1 ]
机构：
[1] Florida Int Univ, Miami, FL USA
[2] City Hope Natl Med Ctr, Med Ctr, Duarte, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6184
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-Mutations
    Willers, H.
    Gurtner, K.
    Benes, C.
    Baumann, M.
    Krause, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1138 - S1139
  • [2] The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.
    Ma, Xiaolong
    Zhang, Ding
    Chen, Shiqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
    Liu, Surui
    Yu, Jin
    Zhang, Hui
    Liu, Jie
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer
    Abraham, Soniya
    Zhang, Janie Yue
    Walther, Zenta
    Parekh, Jay
    Lacy, Jill
    Cecchini, Michael
    Hu, Yiduo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Role of imunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
    Amanam, Idoroenyi
    Mambetsariev, Isa
    Gupta, Rohan
    Achuthan, Srisairant
    Wang, Yingyu
    Pharaon, Rebecca
    Massarelli, Erminia
    Koczywas, Marianna
    Reckamp, Karen
    Salgia, Ravi
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 5086 - +
  • [6] Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
    Cheng Fang
    Chu Zhang
    Wei-Qing Zhao
    Wen-Wei Hu
    Jun Wu
    Mei Ji
    [J]. BMC Medical Genomics, 12
  • [7] Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
    Fang, Cheng
    Zhang, Chu
    Zhao, Wei-Qing
    Hu, Wen-Wei
    Wu, Jun
    Ji, Mei
    [J]. BMC MEDICAL GENOMICS, 2019, 12 (01)
  • [8] TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
    Lee, Eung Bae
    Jin, Guang
    Lee, Shin Yup
    Park, Ji Young
    Kim, Min Jung
    Choi, Jin Eun
    Jeon, Hyo Sung
    Cha, Seung Ick
    Cho, Sukki
    Kim, Chang Ho
    Park, Tae-In
    Jung, Tae Hoon
    Son, Ji-Woong
    Park, Jae Yong
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 698 - 705
  • [9] Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
    Basher, Fahmin
    Saravia, Diana
    Fanfan, Dino
    Cotta, Jared Addison
    Lopes, Gilberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).
    Tomasini, Pascale
    Jao, Kevin
    Kamel-Reid, Suzanne
    Stockley, Tracy
    Tsao, Ming Sound
    Liu, Geoffrey
    Leighl, Natasha B.
    Feld, Ronald
    Bradbury, Penelope Ann
    Pintilie, Melania
    Mascaux, Celine
    Shepherd, Frances A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345